GI Pancreatic

Localized

NeoAdjuvant

- IRB #11256
  OHSU Pancreatic IIT Phase 2 Study of Preoperative Chemotherapy with Abraxane and Gemcitabine Followed by Chemoradiation for Borderline Resectable or Node-Positive Pancreatic

Adjuvant

- IRB #10540
  Celgene APACT Trial
  A phase 3 multicenter, open-label randomized study of nab-Paclitaxel plus Gemcitabine versus Gemcitabine alone as adjuvant therapy in subjects with surgically resected pancreatic adenocarcinoma

First Line Treatment for Advanced or Metastatic Pancreatic Cancer

- IRB #15304
  CC #144525: Study of the Safety, Immunopharmacodynamics and Anti-tumor Activity of Ibrutinib Combined with Gemcitabine and Nab-Paclitaxel in Patients with Metastatic Pancreatic Adenocarcinoma

Metastatic

Second Line Treatment for Advanced or Metastatic Pancreatic Cancer

- IRB #11733
  Phase 2 Proof-of-Concept Study of ACP-196 Alone and in Combination with Pembrolizumab in Subjects with Advanced or Metastatic Pancreatic Cancer

Key

- Open for Enrollment
- In Development
- Enrollment on Hold

www.ohsu.edu/cancer